Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health. Photo courtesy Koda Health.

Home to leading hospitals, universities and health-focused incubators, Houston is a breeding ground for innovative medical technology and breakthroughs that can improve outcomes and lead to a better quality of life for patients.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Corveus Medical

Corveus Medical has developed a novel catheter device that allows cardiologists to perform a splanchnic nerve ablation, restoring the pressure balance in patients with moderate heart failure. Its pre-FDA-approved, minimally invasive solution deactivates a nerve that has been demonstrated to be a root cause behind heart failure progression, which allows physicians to treat patients who have traditionally had few options.

The company, formerly known as Caridian Medical, was founded in 2021 by CEO Tyler Melton and CMO Ishan Kamat. It has participated in incubators such as TMC Biodesign, Y Combinator, MedTech Innovator and Fogarty Innovation and was named one of the 10 most promising life science companies at Texas Life Science Forum in 2022. The company says it will move toward validation and verification testing for its device in Q4 of this year.

FibroBiologics

Regenerative medicine company FibroBioligics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells to repair tissue and modulate the immune system. The cell therapies offer treatments for chronic conditions such as degenerative disc disease, multiple sclerosis and non-healing wounds.

The publicly traded company was founded in 2021 by CEO Pete O'Heeron. It opened a new 10,000-square-foot Houston lab earlier this year to scale up research efforts and pave the way for in-house manufacturing. The company says it plans to launch its first clinical trial for diabetic foot ulcers soon, representing the transition of its fibroblast technology to the clinic setting.

Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

NanoEar

NanoEar has miniaturized hearing aid technology so that it can be implanted across the eardrum, allowing adults with age-related hearing loss to enjoy better sound quality than they would with behind-the-ear hearing aids.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, developed the technology, and the company was founded in 2016 with CFO Willem Vermaat and COO Michael Moore. The company participated in the TMC Innovation Institute in 2016. It has issued nine U.S. patents and performed successful human cadaver and animal proof-of-concept experiments. Its next step is developing a prototype.

Wellysis USA

Wellysis USA Inc. works to detect heart rhythm disorders with its continuous ECG/EKG monitor with AI reporting. Its S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge. The device weighs only 9 grams, is waterproof and designed to be comfortable to wear, and is considered to have a high detection rate for arrhythmias. It is ideally suited for patient-centric clinical trials to help physicians make diagnoses faster, cheaper and more conveniently.

It was established in Houston in 2023 and participated in the JLABS SFF Program the same year. It closed a $12 million series B last year. It was founded by CEO Young Juhn, CTO Rick Kim, CFO JungSoo Kim and chief strategy officer JoongWoo Kim.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

3 Houston health tech companies join global accelerator cohort

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

  • Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
  • Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
  • CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.
Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

Houston organizations announce 10 most promising life science startups

future of health care

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Ares Immunotherapy

Photo via Getty Images

Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

Corveus Medical

Photo courtesy of TMC

Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

"We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

Drusolv Therapeutics

Photo via Pexels

Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

EMPIRI

Photo via jlabs.jnjinnovation.com

Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

"Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

Lapovations

Photo via Getty Images

Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

"Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

Maxwell Biosciences

Photo by Chokniti Khongchum from Pexels

Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

NeuraStasis

Image via neurastasis.com

Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

Vena Medical

Image via venamed.ca

Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

Vivifi Medical

Photo courtesy of TMC

Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

XN Health

Image via xn-health.com

XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA awards Texas Space Commission role in $10M aerospace workforce initiative

space hub

The Texas Space Commission is one of seven organizations tapped by NASA to lead the space agency's new state and regional Skilled Technical Workforce Hubs.

The $10.5 million initiative aims to help foster the next generation of skilled workers in the aerospace industry.

Through the new program, the hubs will work together over the next three years to meet growing industry needs by aligning “industry employers, community colleges, high school career and technical education programs, and workforce systems,” according to a news release from NASA.

It aims to create clear pathways for workers in technical jobs, like welding, electrical work and machining, plus other jobs that require advanced STEM knowledge but do not require a bachelor’s degree.

“The need for technical talent is already urgent and will only continue to grow as we return humanity to the Moon and set our sights on Mars and beyond,” Elaine Ho, associate administrator for the Office of STEM Engagement at NASA, said in the release. “NASA is uniquely positioned to be the catalyst and convener that accelerates America’s aerospace workforce development and fosters the next generation of technicians.”

As part of the initiative, the TSC plans to launch the statewide network known as the Texas Space STEM Alliance (TSSA). According to a TSC release, the TSSA will link up schools, colleges, workforce groups and aerospace companies to build a pipeline for space-industry workers.

Additionally, the TSC is developing the Texas Aerospace Pathways Plus (TAP+) portal to consolidate information on training programs, internships, apprenticeships, employment opportunities and scholarships, while also identifying regional gaps in workforce opportunities.

Other state and regional organizations to receive the award include:

  • Antelope Valley Community College District in Lancaster, California
  • Georgia Tech Research Corporation
  • Minnesota State Colleges and Universities
  • Southern Utah University
  • Space Florida
  • State Board for Community Colleges and Occupation Education, Arapahoe Community College in Littleton, Colorado

The Houston area is home to more than 43,000 aerospace and aviation professionals, according to the Greater Houston Partnership. The Texas Space Commission has been awarded $150 million for 24 projects since being established to increase the state’s space economy in 2023.

The funding for the NASA state hubs comes from NASA’s Office of STEM Engagement through its Next Gen STEM Project.

Amazon's robotaxi service Zoox rolls out in 'sprawling' Houston market

On the Road

Amazon-owned robotaxi ride-hailing service Zoox is zooming into Houston in September, becoming the latest robotaxi operator jockeying for local riders.

Initially, self-driving retrofitted SUVs with safety drivers on board will serve downtown Houston, centrally located tourist hotspots, and certain residential neighborhoods. The SUVs will test Houston roads before Zoox rolls out autonomous robotaxis here, the company says.

Zoox takes Houston for a test drive

At the outset, Zoox says, a limited number of vehicles will be driven by people to gather data about Houston roads.

Zoox test drive Photo courtesy of Zoox

“This helps create a detailed picture of each street, from road geometry to traffic lights,” the company says. “Once we have mapped out an area, we will test autonomous driving capabilities. Safety and operational readiness govern the pace of our rollout.”

Zoox says its robotaxi differs from vehicles operated by other ride-hailing services.

The all-electric robotaxi “is purpose-built for autonomous ride-hailing and designed for riders from day one,” the company says. “It has no traditional driving controls and instead has carriage-style seating, sliding glass doors, and features that let the rider personalize their journey.”

To help manage the fleet, Zoox plans to open a depot in Houston for vehicle charging and maintenance, a representative says via email.

Along with Houston, Zoox is launching this month in San Diego. The ride-hailing service already operates in Austin, Dallas, Atlanta, Las Vegas, Los Angeles, Miami, Phoenix, the San Francisco Bay Area, Seattle, and Washington, D.C.

Zoox breaks into “sprawling” Houston market

Zoox describes Houston as its “most sprawling market to date.”

“Driving here means navigating complex service-road networks, unique merging scenarios, and challenging environmental conditions, including severe heat, heavy rain, and urban flooding,” the company says. “It’s a rigorous test of our technology across geography and terrain.”

Zoox will join two other autonomous ride-hailing services in Houston:

  • Waymo began rolling in Houston in February. Alphabet, the parent company of Google, owns Waymo.
  • Electric vehicle manufacturer Tesla began offering robotaxi services earlier this year.

A third Zoox competitor is arriving within the next year. A partnership comprising rideshare provider Uber, EV manufacturer Lucid, and autonomous technology company Nuro plans to launch a robotaxi service in Houston by mid-2027.

---

This article originally appeared on CultureMap.com.

Houston energy giant Shell lists local headquarters for sale for $325M

On the Market

Energy giant Shell has put its U.S. headquarters in Houston’s Energy Corridor on the market and is exploring the sale of its U.S. chemical business.

Green Street News reported Shell just listed its longtime Energy Corridor campus at 150 N. Dairy Ashford Road. The asking price is $325 million, The Real Deal reported. Shell plans to lease back half of the nearly 1.5 million-square-foot Woodcreek campus for 15 years.

A sale-leaseback deal could transform the 43.6-acre campus into a multitenant hub, CoStar News reported.

“Houston is a critical hub for Shell globally and the headquarters of our U.S. businesses,” a Shell spokesperson told the Houston Business Journal. “We remain committed to Houston and are evaluating opportunities to optimize our Woodcreek campus as part of our ongoing review of workplace needs while maintaining a strong presence in the city.”

Shell occupied its first building at the West Houston campus in 1980. The company employs more than 6,000 people in Texas.

Shell is one of the highest-profile businesses occupying space in the Energy Corridor. It’s home to 67,000 workers, more than 27 million square feet of office and mixed-use space, and 3.8 million square feet of retail and restaurant space.

Shell considers $8B sale of chemical business
As the company seeks to unload its Woodcreek campus, The Financial Times reported Shell is looking into selling its U.S. chemical business. The price tag: $8 billion.

Potential buyers include Spring-based ExxonMobil and Houston-based LyondellBasell.

Shell operates four chemical plants in Texas, Louisiana and Pennsylvania, producing an array of chemicals for use in plastics, detergents and pharmaceuticals.

Shell CEO Wael Sawan said last year that the company had spent $45 billion in capital “that is underperforming for us,” split between its chemical business and renewable energy arm.

Shell also agreed to sell its solar and wind power business in India this summer. Read more here.

---

This article originally appeared on EnergyCapitalHTX.com.